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Psychotropic actions of citalopram  
and escitalopram
Citalopram is a serotonin-selective reuptake 
inhibitor (SSRI) widely used in the treatment of 
major depression and sometimes also anxiety-
-associated conditions, obsessive compulsive 
disorder and behavior disturbances associated 
with dementia [1, 2]. Citalopram is relatively well 
tolerated and has been considered to have compa-
ratively low potential for drug–drug interactions 
and anti-adrenergic and anti-cholinergic effects, 
making it an attractive treatment option for elderly 
patients [1, 2]. The drug is chiral and the serotonin 
reuptake inhibitory activity of citalopram resides 
in the S(+)-enantiomer (available as escitalopram) 
with no therapeutic benefit of the R(–)-enantiomer. 
There is limited evidence that at equivalent doses 
(i.e. matched concentrations of the S-enantiomer), 
escitalopram is more effective clinically than is 
citalopram, raising the possibility of a potential in-
hibitory effect of the R-enantiomer [3–5]. Data from 
studies, in which serotonin reuptake transporter 
(SERT) occupancy has been examined in humans, 
suggest that on repeated dosing with racemic ci-
talopram, R-citalopram levels may exceed those of 
the S-enantiomer, leading to reduced S-citalopram 
occupancy of SERT [6].
Citalopram, escitalopram  
and QT prolongation
A number of psychotropic drugs are associated 
with prolongation of rate-corrected QT (QTc) inter-
val and the associated risk of torsades de pointes 
(TdP) arrhythmia (see: www.crediblemeds.org 
and [7, 8]). Citalopram has been reputed to have 
a good safety profile within the clinical concentration 
range making it an attractive alternative to tricyclic 
antidepressants [2, 9]. However, there is some 
evidence of QT prolongation and arrhythmia with 
citalopram (for reviews see [7, 8, 10]). Reviews of 
data from United States and Swedish adverse effect 
registries note ~20 cases of TdP associated with 
citalopram [8, 11], with a number of additional case 
reports in the literature (for a recent review see: 
[12]). Some case reports of QT prolongation have 
also now emerged for escitalopram (e.g. [13–16]).
Potential dangers with normal use of citalo-
pram came to prominence in safety updates from 
the United States Food and Drug Administration 
(FDA) [17, 18] as well as from other regulato-
ry agencies including the European Medicines 
Agency (EMA) [19] and United Kingdom Medi-
cines and Healthcare Products Regulatory Agen-
cy (MHRA) [20]. In August of 2011 [17] and in 
a subsequent update in March 2012 [18], the FDA 
produced revised recommendations and warnings 
for citalopram, limiting the maximum daily dose 
for all patients and reducing this further for older 
patients. The safety advisory information resulted 
from evaluation of ‘thorough QT’ data from rando-
mized, double-blind, placebo-controlled cross-over 
human subject studies on citalopram and escita-
lopram. Dose-dependent QTc prolongation was 
found for both drugs in healthy volunteers, with 
greater effects for citalopram than therapeutically 
equivalent concentrations of escitalopram. The 
extent of QTc prolongation seen with given doses 
of citalopram compared to therapeutically equiva-
lent escitalopram doses was suggestive of cardiac 
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actions of both citalopram enantiomers. Indeed, the 
FDA safety announcement included a speculation 
that whilst antidepressant effects of citalopram are 
limited to the S-enantiomer, the difference between 
the two forms of drug on the QTc interval “presu-
mably means that the QT effects are not limited 
to the S-isomer” [18, 21].
Citalopram and hERG channel inhibition
Virtually all drugs associated with QTc interval 
share in common the ability to produce pharma-
cological inhibition of ion channels mediating the 
cardiac rapid delayed rectifier potassium current 
(“IKr”) and its cloned equivalent hERG — human-
Ether-à-go-go-Related Gene [22]. IKr regulates ven-
tricular action potential duration and drugs that 
inhibit IKr/hERG consequently delay ventricular 
repolarization and thereby prolong the QTc inter-
val [22]. Citalopram was first reported to inhibit 
the hERG potassium channel in 2002 in a study 
from our laboratory, with a half maximal inhibitory 
concentration (IC50) for hERG current (IhERG) of 
3.97 mM, slightly less than that for another SSRI, 
fluoxetine, in the same study (1.5 mM) [23]. A 
subsequent independent study confirmed hERG 
block by citalopram (with a lower IC50 of 0.95 mM 
[24]). Therapeutic benefits of citalopram for major 
depression appear to require plasma levels of 50 
ng/mL or greater [25], with maximal levels of ~120 
ng/mL at therapeutic doses [9]. With a caveat that 
citalopram is highly lipophilic (so that the possibi-
lity of tissue accumulation must be borne in mind), 
therapeutic total plasma levels are expected to be 
below ~200–300 nM, though raised levels could 
feasibly be attained in overdose or with metabolic 
impairment. hERG block at normal concentrations 
may therefore normally not be high, but could be 
increased in situations of impaired metabolism, 
drug overdose or be exacerbated by cardiac effects 
of electrolyte abnormalities.
Given that the R-enantiomer of citalopram is 
without therapeutic benefit and, consequently, that 
for the racemate twice the total quantity of citalo-
pram is present than for escitalopram for a given 
therapeutically effective dose of the S-enantiomer, 
it has been suggested that moving patients from 
citalopram to escitalopram may be prudent in terms 
of reducing cardiac risk [26]. Until recently, howe-
ver, there has been little or no information as to 
whether or not the two citalopram enantiomers are 
similar in their ability to inhibit hERG. Very recen-
tly, however, Chae et al. [27] have reported an in vi-
tro comparison of the hERG-blocking propensity of 
citalopram and escitalopram, with approximately si-
milar IC50 values for citalopram and of escitalopram. 
The R-enantiomer was not directly investigated 
in that study [27]. We have compared S(+), R(–) 
citalopram enantiomers and the racemic mixture 
on hERG channels using patch clamp recording at 
physiological temperature to elicit IhERG (cf [28]). 
As shown in Figures 1A–C, equal concentrations 
of citalopram, escitalopram and R-citalopram 
produced similar levels of IhERG inhibition and con-
centration response relations (shown in Fig. 1D) 
yielded similar IC50 values (of 0.68 ± 0.08 µM, 
0.70 ± 0.06 µM and 0.67 ± 0.02 µM) for citalopram, 
escitalopram and R-citalopram respectively, under 
our recording conditions. These results comple-
ment and extend the recent findings of Chae et al. 
[27] and demonstrate clearly that, whilst only the 
S-citalopram enantiomer is of psychotropic value, 
both S(+) and R(–) citalopram enantiomers can be 
expected to act on IKr/hERG acutely and, thereby, 
to delay repolarization.
Limiting cardiac risk
A logical conclusion from the information now 
available on hERG-blocking actions of citalopram 
enantiomers together with the thorough QT data 
reported by the FDA [18] is that escitalopram 
should confer a lower cardiac risk than citalopram 
for therapeutically equivalent concentrations 
and therefore should be used clinically in place 
of racemic citalopram. Whilst our own findings 
(Fig. 1) support such a notion, some qualification 
is prudent at this time. First, it is known that ad-
ditional concomitant ion channel blocking effects 
can mitigate consequences of hERG channel 
inhibition and citalopram has been found to exert 
an additional weak inhibition of cardiac L-type 
Ca current (ICa,L) and to modify ICa,L kinetics [23, 
24, 29]. It is feasible that this weak action on ICa,L 
may mitigate effects of hERG blockade at high 
citalopram concentrations. At present it is not yet 
fully established how these two channel effects of 
citalopram interact and, indeed, whether the ICa,L 
action of citalopram is stereoselective. Additional 
information on these points would be helpful. 
Second, cardiac side effects of citalopram need 
not commence immediately following dosing/in-
gestion. One mechanism for delayed drug effects 
on the QTc interval is through inhibition of hERG 
channel trafficking to the cell membrane but, 
whilst there is some evidence that citalopram and 
escitalopram are in principle able to produce this 
effect [27], marked suppression of hERG function 
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through this mechanism appears likely to require 
comparatively high drug concentrations ([27] and 
Zhang and Hancox, unpublished). An alternative 
possibility is that delayed citalopram effects may 
involve accumulation not simply of citalopram 
itself but also of citalopram’s main metabolite 
desmethylcitalopram [30]. We have obtained 
evidence that desmethylcitalopram can indeed 
inhibit hERG, albeit with slightly reduced poten-
cy compared to the parent compound (Fig. 1E). 
At this time we do not know how the parent drug 
and metabolite interact when hERG channels 
are exposed to both molecules simultaneously or 
whether the inhibitory effect of the metabolite is 
stereoselective. This information would be also 
useful to obtain. Third, a recent analysis of case 
reports of TdP with SSRI use highlighted female 
sex and hypokalemia as present in a number of 
TdP cases with citalopram [12]. Whilst these are 
known risk factors in general for drug-induced 
TdP [31], specific mechanistic information would 
be valuable as to how they exacerbate cardiac 
actions of citalopram. However, whilst it is im-
portant for these qualifications to be stated, it ne-
vertheless seems reasonable to agree with a view 
that R-citalopram may serve largely to contribute 
to unwanted cardiac effects of citalopram and, 
therefore, that the ability in clinical practice to 
replace citalopram with lower dose formulations 
of the S-enantiomer may be of significant value 
in respect of reducing cardiac risk [26].
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Figure 1. Comparative inhibition of hERG potassium channels by citalopram enantiomers; A–C. Upper traces show 
representative traces of IhERG elicited from HEK293 cells expressing hERG by the voltage clamp protocol shown in 
the lower panel, in control and after 1 mM of citalopram (A), escitalopram (B), R(–) citalopram (C). D. Mean (± SEM) 
concentration-response plots, overlain, for inhibition of IhERG (tail current) by citalopram, escitalopram and R(–) citalo-
pram. IC50 values are given in the main text. Hill-coefficient values for citalopram, escitalopram and R(–) citalopram 
were respectively: 0.86 ± 0.09, 0.81 ± 0.06, 0.99 ± 0.03; E. Mean (±SEM) concentration-response plots, overlain, 
for citalopram and desmethycitalopram. IC50 values were, respectively, 0.68 ± 0.08 mM and 1.05 ± 0.17 mM (Hill co-
-efficients 0.86 ± 0.09 and 0.78 ± 0.11); n ≥ 5 cells per data-point in D and E.
456 www.cardiologyjournal.org
Cardiology Journal 2014, Vol. 21, No. 5
References
1.   Pollock BG. Citalopram: A comprehensive review. Expert Opin 
Pharmacother, 2001; 2: 681–698.
2.   Keller MB. Citalopram therapy for depression: A review of 
10 years of European experience and data from U.S. clinical trials. 
J Clin Psychiatry, 2000; 61: 896–908.
3.   Storustovu S, Sanchez C, Porzgen P et al. R-citalopram functio-
nally antagonises escitalopram in vivo and in vitro: evidence for 
kinetic interaction at the serotonin transporter. Br J Pharmacol, 
2004; 142: 172–180.
4.   Sanchez C. The pharmacology of citalopram enantiomers: The 
antagonism by R-citalopram on the effect of S-citalopram. Basic 
Clin Pharmacol Toxicol, 2006; 99: 91–95.
5.   Zhong H, Haddjeri N, Sanchez C. Escitalopram, an antidepressant 
with an allosteric effect at the serotonin transporter: A review of 
current understanding of its mechanism of action. Psychophar-
macology (Berl), 2012; 219: 1–13.
6.   Kasper S, Sacher J, Klein N et al. Differences in the dynamics of 
serotonin reuptake transporter occupancy may explain superior 
clinical efficacy of escitalopram versus citalopram. Int Clin Psy-
chopharmacol, 2009; 24: 119–125.
7.   Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac 
arrhythmia, and sudden death. J Clin Psychopharmacol, 2003; 23: 
58–77.
8.   Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by 
psychotropic drugs and the risk of torsade de pointes. Dtsch 
Arztebl Int, 2011; 108: 687–693.
9.   Parker NG, Brown CS. Citalopram in the treatment of depres-
sion. Ann Pharmacother, 2000; 34: 761–771.
10.   Vieweg WV, Hasnain M, Howland RH et al. Citalopram, QTc 
interval prolongation, and torsade de pointes. How should we 
apply the recent FDA ruling? Am J Med, 2012; 125: 859–868.
11.   Astrom-Lilja C, Odeberg JM, Ekman E, Hagg S. Drug-induced 
torsades de pointes: A review of the Swedish pharmacovigilance 
database. Pharmacoepidemiol Drug Saf, 2008; 17: 587–592.
12.   Kogut C, Breden-Crouse E, Vieweg WV et al. Selective serotonin 
reuptake inhibitors and torsades de pointes. New concepts and 
new directions derived from systematic review of case reports. 
Ther Adv Drug Safe, 2013; 4: 189–198. 
13.   Tseng PT, Lee Y, Lin YE, Lin PY. Low-dose escitalopram for 
2 days associated with corrected QT interval prolongation in 
a middle-aged woman: A case report and literature review. Gen 
Hosp Psychiatry, 2012; 34: 210–215.
14.   Mohammed R, Norton J, Geraci SA, Newman DB, Koch CA. Pro-
longed QTc interval due to escitalopram overdose. J Miss State 
Med Assoc, 2010; 51: 350–353.
15.   van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of 
escitalopram overdose. Ann Emerg Med, 2009; 54: 404–408.
16.   Baranchuk A, Simpson CS, Methot M, Gibson K, Strum D. Cor-
rected QT interval prolongation after an overdose of escitalo-
pram, morphine, oxycodone, zopiclone and benzodiazepines. Can 
J Cardiol, 2008; 24: e38–e40.
17.   FDA Drug Safety Communication: Abnormal heart rhythms associa-
ted with high doses of Celexa (citalopram hydrobromide) http://www.
fda.gov/Drugs/DrugSafety/ucm269086.htm (accessed May 23 2014).
18.   FDA Drug Safety Communication: Revised recommendations 
for Celexa (citalopram hydrobromide) related to a potential risk 
of abnormal heart rhythms with high doses. http://www.fda.gov/ 
/drugs/drugsafety/ucm297391.htm (accessed May 23 2014).
19.   Pharmacoviglence working party (PhVWP) November 2011. 
Escitalopram: Risk of QT interval prolongation. http://www.
ema.europa.eu/docs/en_GB/document_library/Report/2011/11/
WC500117988.pdf (accessed May 23 2014).
20.   Citalopram and escitalopram: QT interval prolongation: New maxi-
mum daily dose restrictions (including in elderly patients), contrain-
dications, and warnings http://www.mhra.gov.uk/Safety-information/ 
/DrugSafetyUpdate/CON137769 (accessed May 23 2014).
21.   Temple R, Laughren T, Stockbridge N. Removal from labeling of 
60-mg citalopram dose. Pharmacoepidemiol Drug Saf, 2012; 21: 
784–786.
22.   Hancox JC, McPate MJ, El Harchi A, Zhang YH. The hERG po-
tassium channel and hERG screening for drug-induced torsades 
de pointes. Pharmacology Therapeutics, 2008; 119: 118–132.
23.   Witchel HJ, Pabbathi VK, Hofmann G, Paul AA, Hancox JC. 
Inhibitory actions of the selective serotonin re-uptake inhibitor 
citalopram on HERG and ventricular L-type calcium currents. 
FEBS Lett, 2002; 512: 59–66.
24.   Fossa AA, Gorczyca W, Wisialowski T et al. Electrical alternans 
and hemodynamics in the anesthetized guinea pig can discrimi-
nate the cardiac safety of antidepressants. J Pharmacol Toxicol 
Methods, 2007; 55: 78–85.
25.   Ostad HE, Tadic A, Wagner S et al. Association between cita-
lopram serum levels and clinical improvement of patients with 
major depression. J Clin Psychopharmacol, 2011; 31: 281–286.
26.   Keller DL. Prescribe escitalopram instead of citalopram. Am J Med, 
2013; 126: e21.
27.   Chae YJ, Jeon JH, Lee HJ et al. Escitalopram block of hERG 
potassium channels. Naunyn Schmiedebergs Arch Pharmacol, 
2014; 387: 23–32.
28.   Zhang YH, Cheng H, Alexeenko VA, Dempsey CE, Hancox JC. 
Characterization of recombinant hERG K+ channel inhibition 
by the active metabolite of amiodarone desethyl-amiodarone. 
J Electrocardiol, 2010; 43: 440–448.
29.   Zahradnik I, Minarovic I, Zahradnikova A. Inhibition of the cardiac 
L-type calcium channel current by antidepressant drugs. J Phar-
macol Exp Ther, 2008; 324: 977–984.
30.   Tarabar AF, Hoffman RS, Nelson L. Citalopram overdose: Late 
presentation of torsades de pointes (TdP) with cardiac arrest. 
J Med Toxicol, 2008; 4: 101–105.
31.   Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused 
by noncardiac drugs. Prog Cardiovasc Dis, 2003; 45: 415–427.
www.cardiologyjournal.org 457
Yihong Zhang et al., Cardiac safety of citalopram
